{"id":42482,"date":"2025-09-29T17:56:22","date_gmt":"2025-09-29T09:56:22","guid":{"rendered":"https:\/\/flcube.com\/?p=42482"},"modified":"2025-09-29T17:56:22","modified_gmt":"2025-09-29T09:56:22","slug":"sinopharm-secures-nmpa-approval-for-quadrivalenthpv-vaccine","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42482","title":{"rendered":"Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>China\u2019s Sinopharm Group Co., Ltd.<\/strong> (Chengdu Institute of Biological Products, a subsidiary of the China National Biotec Group \u2013 CNBG) announced that the National Medical Products Administration (NMPA) has granted marketing approval for its first domestically produced <strong>quadrivalent human papillomavirus (HPV) vaccine<\/strong>. The vaccine is produced using a yeast\u2011expression platform (Pichia\u202fpastoris) that aligns with international best\u2011practice standards.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-the-quadrivalenthpv-vaccine-brings\">What the QuadrivalentHPV Vaccine Brings<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Expanded Protection<\/strong> \u2013 While existing domestic bivalent vaccines target high\u2011risk HPV\u201116 and HPV\u201118 (the primary culprits of cervical cancer), the new quadrivalent formulation also covers low\u2011risk HPV\u20116 and HPV\u201111, the viruses that cause genital warts.<\/li>\n\n\n\n<li><strong>Yeast\u2011Based Manufacturing<\/strong> \u2013 The Pichia\u202fpastoris system offers high yield, cost\u2011effectiveness, and scalability, positioning the vaccine as a competitive alternative to cell\u2011culture and recombinant protein platforms.<\/li>\n\n\n\n<li><strong>Regulatory Milestone<\/strong> \u2013 The NMPA approval confirms the vaccine\u2019s safety, efficacy, and quality, marking the first time a fully domestic quadrivalent HPV product has cleared China\u2019s stringent regulatory pathway.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Public Health Impact<\/strong> \u2013 By filling the gap left by bivalent vaccines, the quadrivalent product enhances national immunization coverage and could reduce the incidence of genital warts\u2014an important but often overlooked public\u2011health burden.<\/li>\n\n\n\n<li><strong>Domestic Innovation Edge<\/strong> \u2013 The approval underscores CNBG\u2019s growing capability in next\u2011generation vaccine development and may spur further investment in yeast\u2011based biologics across the country.<\/li>\n\n\n\n<li><strong>Global Expansion Potential<\/strong> \u2013 With a proven manufacturing platform and regulatory success in China, Sinopharm is well\u2011positioned to seek approvals in other emerging markets, expanding its footprint beyond the domestic front.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>China\u2019s Sinopharm Group Co., Ltd. (Chengdu Institute of Biological Products, a subsidiary of the China&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42483,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[15,2311,12],"class_list":["post-42482","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-product-approvals","tag-sinopharm-group-company","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s Sinopharm Group Co., Ltd. (Chengdu Institute of Biological Products, a subsidiary of the China National Biotec Group \u2013 CNBG) announced that the National Medical Products Administration (NMPA) has granted marketing approval for its first domestically produced quadrivalent human papillomavirus (HPV) vaccine. The vaccine is produced using a yeast\u2011expression platform (Pichia\u202fpastoris) that aligns with international best\u2011practice standards.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42482\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine\" \/>\n<meta property=\"og:description\" content=\"China\u2019s Sinopharm Group Co., Ltd. (Chengdu Institute of Biological Products, a subsidiary of the China National Biotec Group \u2013 CNBG) announced that the National Medical Products Administration (NMPA) has granted marketing approval for its first domestically produced quadrivalent human papillomavirus (HPV) vaccine. The vaccine is produced using a yeast\u2011expression platform (Pichia\u202fpastoris) that aligns with international best\u2011practice standards.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42482\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-29T09:56:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2907.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42482#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42482\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine\",\"datePublished\":\"2025-09-29T09:56:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42482\"},\"wordCount\":264,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42482#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2907.webp\",\"keywords\":[\"Product approvals\",\"Sinopharm Group Company\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42482#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42482\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42482\",\"name\":\"Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42482#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42482#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2907.webp\",\"datePublished\":\"2025-09-29T09:56:22+00:00\",\"description\":\"China\u2019s Sinopharm Group Co., Ltd. (Chengdu Institute of Biological Products, a subsidiary of the China National Biotec Group \u2013 CNBG) announced that the National Medical Products Administration (NMPA) has granted marketing approval for its first domestically produced quadrivalent human papillomavirus (HPV) vaccine. The vaccine is produced using a yeast\u2011expression platform (Pichia\u202fpastoris) that aligns with international best\u2011practice standards.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42482#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42482\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42482#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2907.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2907.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42482#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s Sinopharm Group Co., Ltd. (Chengdu Institute of Biological Products, a subsidiary of the China National Biotec Group \u2013 CNBG) announced that the National Medical Products Administration (NMPA) has granted marketing approval for its first domestically produced quadrivalent human papillomavirus (HPV) vaccine. The vaccine is produced using a yeast\u2011expression platform (Pichia\u202fpastoris) that aligns with international best\u2011practice standards.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42482","og_locale":"en_US","og_type":"article","og_title":"Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine","og_description":"China\u2019s Sinopharm Group Co., Ltd. (Chengdu Institute of Biological Products, a subsidiary of the China National Biotec Group \u2013 CNBG) announced that the National Medical Products Administration (NMPA) has granted marketing approval for its first domestically produced quadrivalent human papillomavirus (HPV) vaccine. The vaccine is produced using a yeast\u2011expression platform (Pichia\u202fpastoris) that aligns with international best\u2011practice standards.","og_url":"https:\/\/flcube.com\/?p=42482","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-29T09:56:22+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2907.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42482#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42482"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine","datePublished":"2025-09-29T09:56:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42482"},"wordCount":264,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42482#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2907.webp","keywords":["Product approvals","Sinopharm Group Company","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42482#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42482","url":"https:\/\/flcube.com\/?p=42482","name":"Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42482#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42482#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2907.webp","datePublished":"2025-09-29T09:56:22+00:00","description":"China\u2019s Sinopharm Group Co., Ltd. (Chengdu Institute of Biological Products, a subsidiary of the China National Biotec Group \u2013 CNBG) announced that the National Medical Products Administration (NMPA) has granted marketing approval for its first domestically produced quadrivalent human papillomavirus (HPV) vaccine. The vaccine is produced using a yeast\u2011expression platform (Pichia\u202fpastoris) that aligns with international best\u2011practice standards.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42482#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42482"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42482#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2907.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2907.webp","width":1080,"height":608,"caption":"Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42482#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2907.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42482"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42482\/revisions"}],"predecessor-version":[{"id":42485,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42482\/revisions\/42485"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42483"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}